BioNTech SE (ETR:22UA)
Germany
· Delayed Price · Currency is EUR | Market Cap | 19.89B |
| Revenue (ttm) | 3.15B |
| Net Income (ttm) | -571.60M |
| Shares Out | n/a |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,027 |
| Average Volume | 50,645 |
| Open | 83.40 |
| Previous Close | 82.90 |
| Day's Range | 81.90 - 83.80 |
| 52-Week Range | 73.15 - 124.90 |
| Beta | 1.31 |
| RSI | 38.67 |
| Earnings Date | Mar 10, 2026 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
BioNTech Secures Majority Of CureVac Shares As Exchange Offer Advances
(RTTNews) - BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
BioNTech (BNTX) Advances with CureVac Acquisition
BioNTech (BNTX) Advances with CureVac Acquisition
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati...
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths
Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.
BioNTech (BNTX) Q3 2025 Earnings Call Transcript
BioNTech (BNTX) Q3 2025 Earnings Call Transcript
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Moves Forward with CureVac Acquisition
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3
Understood! Please provide the article or its content so I can generate the SEO-friendly meta description.
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
MAINZ, Germany, November 26, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the approval of matters relating to the exchange offer (the “Offer”) for all outstanding shares of CureVac N....
CureVac Reveals Key Voting Outcomes from Extraordinary Shareholder Meeting
CureVac’s latest Extraordinary General Meeting delivered near-unanimous backing for BioNTech’s exchange offer and key merger decisions, reshaping the company’s future.
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations
Pfizer Cuts BioNTech Stake by More Than Half
Pfizer Cuts BioNTech Stake by More Than Half
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up
Pfizer Inc said on Thursday said that it will sell 54.7% of its stake in German drugmaker BioNTech SE , over five years after both firms formed an alliance that yielded a vaccine to combat the deadly ...
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Pfizer (NYSE: PFE) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE (NASDAQ: BNTX).
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Pfizer (NYSE: PFE) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE (NASDAQ: BNTX). BNTX is among today's weakest performers. See the full breakdown here It seeks...
4 stocks to watch on Thursday: DIS, RIO, JD, BNTX
DIS, RIO, JD, BNTX are the four stocks to watch on Thursday
Pfizer Plans to Divest BioNTech Stake, Impacting BNTX Shares
Pfizer Plans to Divest BioNTech Stake, Impacting BNTX Shares
BioNTech (BNTX) Concludes Successful Stock Offering
BioNTech (BNTX) Concludes Successful Stock Offering
Pfizer (PFE) Plans to Divest Remaining BioNTech Stake
Pfizer (PFE) Plans to Divest Remaining BioNTech Stake
Pfizer is said to divest remaining stake in BioNTech
BioNTech says collaboration with Pfizer remains unchanged
BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech...